This content is only available to 2025 ASCRS Annual Meeting physician registrants
To log in, click the teal "Login" button in the upper right-hand corner of this page. If you are logged in but still do not have access, please check your 2025 Annual Meeting registration.
A documented OCP case started Rituximab to control the disease activity. The inflammation subsided 6 months after taking the 1st dose. After counseling the patient and his son, 2 areas-3 clock hours- limbal stem cells from his son were taken. Periotomy was done to the patient left eye with removal of fibrous tissues over the cornea. Stem cells were sutured over one layer of amniotic membrane.